FORLENVY

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 12 Feb 2025 filing date already counts against anyone who files later.

Record

Serial number

99038944

Mark type

Stylized text

Filed

12 Feb 2025

Published for opposition

02 Sept 2025

Attorney of record

Aaron D. Hendelman

Goods and services

• Class 005 — Pharmaceuticals: Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of and prevention of musculoskeletal, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, and muscle atrophy related diseases and disorders; pharmaceutical preparations for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; therapeutic pharmaceutical for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; therapeutic pharmaceuticals for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes
• Class 040 — Treatment of materials: Custom manufacturing of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies; custom manufacturing of pharmaceuticals; contract manufacturing in the field of pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing
• Class 042 — Scientific and technological services: Medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information in the fields of pharmaceuticals, biotechnology, and clinical trials; pharmaceutical research and development; pharmaceutical products development; research and development in the field of biotechnology
• Class 044 — Medical, beauty and agricultural services: Providing information in the fields of pharmaceuticals, therapeutics, healthcare, medicines, vaccines, health conditions, health awareness and treatment options; medical information services, namely, providing information related to healthcare, diseases, disorders, and treatment options; online information services, namely, providing a website related to healthcare, health awareness, medicines, vaccines, diseases, disorders, and treatment options

Owner

• Avidity Biosciences, Inc., San Diego, CA, US
• Avidity Biosciences, Inc., San Diego, CA, US

Prosecution history

• 05 Mar 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
• 05 Mar 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
• 05 Mar 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
• 05 Mar 2026 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
• 05 Mar 2026 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
• 28 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 05 Sept 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
• 05 Sept 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
• 05 Sept 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
• 02 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 02 Sept 2025 — PUBLISHED FOR OPPOSITION
• 27 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 26 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 21 Jul 2025 — ASSIGNED TO EXAMINER
• 11 Jul 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED